Organon & Co. (OGN) To Go Ex-Dividend on August 14th

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Friday, July 31st. Shareholders of record on Friday, August 14th will be given a dividend of 0.02 per share on Thursday, September 10th. This represents a c) dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th.

Organon & Co. has a payout ratio of 2.0% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Organon & Co. to earn $3.44 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.3%.

Organon & Co. Stock Up 0.3%

Shares of NYSE:OGN opened at $13.65 on Wednesday. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43. The business has a fifty day moving average of $13.50 and a two-hundred day moving average of $10.65. The stock has a market cap of $3.59 billion, a P/E ratio of 17.73, a PEG ratio of 1.26 and a beta of 1.55. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.66.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. BNP Paribas Exane reissued a “neutral” rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Weiss Ratings cut shares of Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their target price for the stock from $5.00 to $14.00 in a research note on Tuesday, April 28th. Finally, Zacks Research upgraded shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Five research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Organon & Co. currently has a consensus rating of “Reduce” and a consensus price target of $11.40.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.